New test could spot tumours that dodge radiotherapy
NCT ID NCT06787053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose more effective treatments for these hard-to-treat tumours.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Christie NHS Foundation Trust
RECRUITINGManchester, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A second look: MRI screening may spot hidden prostate cancers
- Can an antiviral make radiation more effective against cervical cancer?
- Can precision protons spare the bowel in prostate cancer?